Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424937 | 1.00 | LMNA (0.51) | LMNAKDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL1138018 | 0.84 | KDM4E (0.53) | LMNAKDM4EKMT2APTK2L3MBTL1 | |
| SCHEMBL15886759 | 0.82 | NPC1 (0.42) | LMNAKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23089265 | 0.79 | RAB9A (0.44) | LMNAKDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL24992536 | 0.79 | HPGD (0.56) | LMNAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30173006 | 0.79 | HPGD (0.56) | LMNAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16685587 | 0.79 | KDM4E (0.46) | LMNAKDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL9143700 | 0.79 | KDM4E (0.46) | LMNAKDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL1269767 | 0.79 | RAB9A (0.60) | LMNAKDM4EKMT2ARAB9ANPC1 | |
| SCHEMBL1269422 | 0.79 | TSHR (0.49) | LMNAKDM4EKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2020157474-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157474-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| EP-2943481-B1 | (HETERO)ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2943481-A1 | (HETERO) ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9050344-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050344-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140221346-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221347-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | LMNA 4030/4885KDM4E 1658/4885KMT2A 1507/4885 |
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | LMNA 2576/4885KDM4E 2907/4885KMT2A 1448/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | LMNA 4030/4885KDM4E 1658/4885KMT2A 1507/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | LMNA 2576/4885KDM4E 2907/4885KMT2A 1448/4885 |
| US-20140221347-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, FURIN | LMNA 3167/4885KDM4E 4481/4885KMT2A 4773/4885 |
| US-20140221346-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | LMNA 3225/4885KDM4E 4478/4885KMT2A 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.